CF Foundation's $3.3bn royalty sale will fund drugs, services

The Cystic Fibrosis Foundation's (CFF) $150m investment in therapies developed by Vertex Pharmaceuticals, including Kalydeco (ivacaftor), paid off in a big way: the nonprofit patient advocacy group sold its future royalties from the cystic fibrosis (CF) medicines to Royalty Pharma for $3.3bn.